Next Article in Journal
Self-Assembled Supramolecular Nanoparticles Improve the Cytotoxic Efficacy of CK2 Inhibitor THN7
Next Article in Special Issue
Polyethylene Glycol Exposure with Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol) and Other Therapies Indicated for the Pediatric Population: History and Safety
Previous Article in Journal
In Silico Study, Synthesis, and Cytotoxic Activities of Porphyrin Derivatives
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessArticle
Pharmaceuticals 2018, 11(1), 9;

Improved Intranasal Retentivity and Transnasal Absorption Enhancement by PEGylated Poly-l-ornithine

Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, 3-3165 Higashi-tamagawa Gakuen, Machida, Tokyo 194-8543, Japan
Author to whom correspondence should be addressed.
Received: 28 October 2017 / Revised: 17 January 2018 / Accepted: 19 January 2018 / Published: 25 January 2018
(This article belongs to the Special Issue Polyethylene Glycol (PEG) and PEGylation in Pharmacy)
Full-Text   |   PDF [3304 KB, uploaded 25 January 2018]   |  


We reported that the introduction of polyethylene glycol (PEG) to poly-l-ornithine (PLO), which is an homopolymeric basic amino acid having absorption-enhancement ability, prolonged retention time in an in vitro inclined plate test, probably due to an increase in viscosity caused by PEGylation. The aim of the present study is to investigate whether the introduction of PEG chains to PLO improves intranasal retention and transnasal absorption in vivo. We performed intranasal administration experiments using PLO and PEG-PLO with a model drug, fluorescein isothiocyanate dextran (FD-4), in rats under closed and open systems. In the open system, transition of plasma FD-4 concentration after co-administration with unmodified PLO was low, and the area under the plasma concentration-time curve (AUC) decreased to about 60% of that in the closed system. In contrast, the AUC after co-administration with PEG-PLO in the open system was about 90% of that in the closed system, and the transition of plasma FD-4 concentration and FD-4 absorption profile were similar to those of the closed system. These findings indicate that introducing PEG chains to homopolymeric basic amino acids (HPBAAs) is a very useful method for developing a functional absorption enhancer that can exhibit an efficient in vivo absorption-enhancing effect. View Full-Text
Keywords: poly-l-ornithine (PLO); polyethylene glycol (PEG); absorption enhancer; intranasal administration; retentivity poly-l-ornithine (PLO); polyethylene glycol (PEG); absorption enhancer; intranasal administration; retentivity

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kamiya, Y.; Yamaki, T.; Omori, S.; Uchida, M.; Ohtake, K.; Kimura, M.; Yamazaki, H.; Natsume, H. Improved Intranasal Retentivity and Transnasal Absorption Enhancement by PEGylated Poly-l-ornithine. Pharmaceuticals 2018, 11, 9.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top